Clinical Trial Update: Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases [Phase 2]

View source ↗

Summary

Travere Therapeutics is running a phase 2 pediatric trial of sparsentan for proteinuric glomerular diseases, including Focal Segmental Glomerulosclerosis, Minim…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alport Syndrome
• Focal Segmental Glomerulosclerosis
• Iga Nephropathy
• Iga Vasculitis
• Minimal Change Disease

Drugs mentioned

• Sparsentan (sparsentan)

Snippet

Sponsor: Travere Therapeutics, Inc. | Conditions: Focal Segmental Glomerulosclerosis, Minimal Change Disease | Phase 2 | Status: RECRUITING